



Review

Antimicrobial resistance in *Enterobacteriaceae* in Brazil: focus on β -lactams and polymyxins

Jorge Luiz Mello Sampaio^{a,b,*}, Ana Cristina Gales^{c,*}^a Universidade de São Paulo, Faculdade de Ciências Farmacêuticas, Departamento de Análises Clínicas e Toxicológicas, São Paulo, SP, Brazil^b Fleury Medicina e Saúde, Seção de Microbiologia, São Paulo, SP, Brazil^c Universidade Federal de São Paulo, Escola Paulista de Medicina, Departamento de Medicina Interna, São Paulo, Brazil

ARTICLE INFO

Article history:

Received 7 October 2016

Accepted 7 October 2016

Available online 25 October 2016

Associate Editor: Marina Baquerizo

Keywords:

ESBL

KPC

NDM

Extended spectrum β -lactamasesNew Delhi metallo- β -lactamase*Klebsiella pneumoniae*

carbapenemase

Polymyxin B

Colistin

Antimicrobial resistance

Carbapenemases

Brazil

Enterobacteriaceae

ABSTRACT

During the last 30 years there has been a dissemination of plasmid-mediated β -lactamases in *Enterobacteriaceae* in Brazil. Extended spectrum β -lactamases (ESBL) are widely disseminated in the hospital setting and are detected in a lower frequency in the community setting. Cefotaximases are the most frequently detected ESBL type and *Klebsiella pneumoniae* is the predominant species among ESBL producers. *Klebsiella pneumoniae* carbapenemase-producing *Enterobacteriaceae* became widely disseminated in Brazil during the last decade and KPC production is currently the most frequent resistance mechanism (96.2%) in carbapenem resistant *K. pneumoniae*. To date KPC-2 is the only variant reported in Brazil. Polymyxin B resistance in KPC-2-producing *K. pneumoniae* has come to an alarming rate of 27.1% in 2015 in São Paulo, the largest city in Brazil. New Delhi metallo- β -lactamase was detected in Brazil in 2013, has been reported in different Brazilian states but are not widely disseminated. Antimicrobial resistance in *Enterobacteriaceae* in Brazil is a very serious problem that needs urgent actions which includes both more strict adherence to infection control measures and more judicious use of antimicrobials.

© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The first reports on antimicrobial resistance in Gram-negative rods from Brazil, available at PubMed, were restricted to community-acquired infections. These reports were on sulfadiazine resistance in *Escherichia coli*, *Shigella* and *Salmonella* and dated from 1968.^{1,2} In 1971 chloramphenicol resistance was reported in *Salmonella* Typhi detected in various Brazilian states³ and *Shigella* resistant to multiple antimicrobials

were reported from Rio de Janeiro.⁴ At that time, β -lactam resistance was only reported for ampicillin.

The rise of extended-spectrum β -lactamases

Third generation cephalosporins became available for clinical use in Brazil in early 1980s. In our medical practice, we

* Corresponding authors.

E-mails: sampaio@usp.br (J.L. Sampaio), ana.gales@gmail.com (A.C. Gales).<http://dx.doi.org/10.1016/j.bjm.2016.10.002>1517-8382/© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

have observed resistance to third-generation cephalosporins among *Enterobacteriaceae* since 1985, but the first report of this finding in Brazilian hospitals was published only in 1994, describing a 52% cefepime resistance rate among ceftazidime-resistant *Enterobacteriaceae*.⁵ This was the first published clue on the presence of extended spectrum β -lactamases (ESBLs) in Brazil. In 1997, the first confirmation of ESBL production in *Enterobacteriaceae* from Brazil came out. The authors documented the presence of ESBLs in 72 *K. pneumoniae* clinical isolates, from private and public tertiary hospitals located in Rio de Janeiro and São Paulo, by clavulanic acid inhibition. Of note, they also reported a low susceptibility rates for amikacin (41.4%) and gentamicin (29.6%) but all isolates were still susceptible to imipenem.⁶ A subsequent work, also published in 1997, including 982 consecutive isolates from 18 hospitals, from four different states and seven different cities, was the first publication that could be used to estimate the ESBL rate among *Enterobacteriaceae*. Assuming that resistance to third generation cephalosporins was only due to ESBL production, 16% and 5% of *K. pneumoniae* and *E. coli*, respectively, would be classified as ESBL producers at that time.⁷

The first molecular studies on ESBLs from Brazil came out in 2000, evidencing the predominance of *bla*_{CTX-M} genes and describing the CTX-M-8 enzyme in strains other than *K. pneumoniae* from Rio de Janeiro.⁸ The same group of researchers described the BES-1 and the CTX-M-16 enzymes in strains from the same city.^{9,10} Subsequent surveillance studies evidenced a growing ESBL production rates among *Enterobacteriaceae* collected from inpatients. In 2000, the ESBL production rate in *K. pneumoniae* collected from intensive care units was 59.2%, while these rates in *Enterobacter* spp. and *E. coli* were 19.5% and 14.6%, respectively.¹¹ The most recent study on the diversity of ESBL types in *Enterobacteriaceae* isolated from Brazil refers to 1827 isolates collected during the period between August 2003 and March 2008 in the city of Curitiba, Paraná. CTX-M-2 was the most frequently detected ESBL in all *Enterobacteriaceae* species, except in *Enterobacter aerogenes*, in which a CTX-M-59-producing clone was predominant.¹² Recent studies have reported that ESBL-producing *Enterobacteriaceae* are now detected in a significant rate in outpatients presenting cystitis. In a public institution located in Brasília, the ESBL production rate in *E. coli* collected from July 2013 to April 2014 was 7.1%.¹³ When we reviewed all publication from Brazil about ESBLs, CTX-M-2 was the most frequently detected enzyme and was also detected in the largest number of different *Enterobacteriaceae* species (Table 1).

Plasmid-mediated AmpCs

FOX-5-like and CMY-2-like were the first plasmid-mediated AmpCs (pAmpC) reported in Brazilian isolates. Both enzymes were detected in *E. coli*.^{42,43} The FOX-5-like encoding gene was detected during the DNA sequencing of a 41-kb conjugative plasmid that harbored a *qnrA* gene and a class 1 integron with the *aadB* and *catB3* gene cassettes.⁴³ The CMY-2-like enzyme was detected in four carbapenem-resistant *E. coli* strains, which also possessed alteration in the outer membrane proteins, isolated from a single patient.⁴² Dias and colleagues studied the prevalence of pAmpC among

Table 1 – Extended spectrum β -lactamases detected in *Enterobacteriaceae* in Brazil.

Enzyme	Species
BES-1	<i>Serratia marcescens</i> ⁹
CTX-M-1	<i>K. pneumoniae</i> ¹⁴
CTX-M-2	<i>Enterobacter aerogenes</i> ^{12,15} ; <i>Enterobacter cloacae</i> ^{12,16} ; <i>Escherichia coli</i> ^{12,16-22} ; <i>Klebsiella pneumoniae</i> ^{14,16,21,23-29} ; <i>K. oxytoca</i> ²¹ ; <i>Morganella morganii</i> ^{16,21} ; <i>Proteus mirabilis</i> ^{8,17,21} ; <i>Providencia stuartii</i> ^{16,21,30} ; <i>Salmonella typhimurium</i> ³¹ ; <i>S. marcescens</i> ¹⁷
CTX-M-3	<i>E. coli</i> ²²
CTX-M-8	<i>Citrobacter amalonaticus</i> ⁸ ; <i>Enterobacter cloacae</i> ⁸ ; <i>E. aerogenes</i> ⁸ ; <i>E. coli</i> ^{12,16,22} ; <i>K. pneumoniae</i> ¹⁴
CTX-M-9	<i>Citrobacter freundii</i> ¹⁶ ; <i>E. cloacae</i> ^{10,12} ; <i>E. coli</i> ^{10,12,16,20} ; <i>K. pneumoniae</i> ¹⁶
CTX-M-14	<i>E. coli</i> ^{18,32}
CTX-M-15	<i>E. aerogenes</i> ¹² ; <i>E. cloacae</i> ^{12,33} ; <i>E. coli</i> ^{18,22,32,34} ; <i>K. pneumoniae</i> ^{27,33,35}
CTX-M-16	<i>E. coli</i> ¹⁰ ; <i>E. cloacae</i> ¹⁰
CTX-M-28	<i>K. pneumoniae</i> ²⁴ ; <i>K. oxytoca</i> ²¹
CTX-M-59	<i>E. aerogenes</i> ¹⁵ ; <i>E. cloacae</i> ¹⁵ ; <i>E. coli</i> ^{20,21,27} ; <i>K. pneumoniae</i> ^{21,23,27}
CTX-M-74	<i>E. cloacae</i> ¹⁶
CTX-M-75	<i>P. stuartii</i> ¹⁶
CTX-M-131	<i>P. stuartii</i> ³⁶
GES-1	<i>K. pneumoniae</i> ³⁷
GES-7	<i>K. pneumoniae</i> ³⁸
PER-2	<i>E. cloacae</i> ^{12,15}
SHV-2	<i>K. pneumoniae</i> ; <i>E. coli</i> ²²
SHV-4	<i>K. pneumoniae</i> ³⁹
SHV-5	<i>E. cloacae</i> ¹⁶ ; <i>E. coli</i> ^{16,19,21} ; <i>K. pneumoniae</i> ¹⁶
SHV-12	<i>E. aerogenes</i> ^{12,15} ; <i>E. cloacae</i> ^{12,15} ; <i>K. pneumoniae</i> ^{21,25,35}
SHV-27	<i>K. pneumoniae</i> ^{21,40}
SHV-28	<i>K. pneumoniae</i> ^{21,41}
SHV-31	<i>K. pneumoniae</i> ³⁵
SHV-38	<i>K. pneumoniae</i> ³⁵
SHV-40	<i>K. pneumoniae</i> ³⁸
SHV-45	<i>K. pneumoniae</i> ²¹
SHV-55	<i>K. pneumoniae</i> ²¹
SHV-108	<i>K. pneumoniae</i> ⁴¹
SHV-122	<i>K. pneumoniae</i> ⁴¹
TEM-15	<i>K. pneumoniae</i> ²¹
TEM-115	<i>K. pneumoniae</i> ²¹
TEM-116	<i>K. pneumoniae</i> ³⁸
TEM-135	<i>E. cloacae</i> ¹²

Enterobacteriaceae isolated from a teaching hospital in Rio de Janeiro. In that study pAmpC encoding genes were not detected and the multidrug resistance phenotype observed in five *E. coli* strain was attributed to hyperexpression of chromosomally encoded AmpC.⁴⁴ Very few studies described the frequency of pAmpCs in *Enterobacteriaceae* in Brazil, although pAmpCs are of epidemiological importance, since carbapenem resistance can occur in strains with concomitant permeability alterations and pAmpC expression. A study conducted in a public tertiary hospital from São Paulo included 41 *E. coli*, five *Klebsiella oxytoca*, 65 *Klebsiella pneumoniae*, 18 *P. mirabilis*, and four *Salmonella* spp. detected during the period from January and July 2006 and found a 0.75% plasmid-mediated AmpC production rate and a single isolate producing a CMY-2-like enzyme was identified.⁴⁵ The most recent study on pAmpCs in Brazil evaluated the frequency of plasmid-mediated AmpCs in *E. coli* isolated from urine cultures from both outpatients and inpatients. The frequency

Table 2 – KPC-producing species detected in Brazil.

Species	Location (City, State)	MLST
<i>C. freundii</i>	AL ⁵⁹ ; Duque de Caxias, RJ ⁶⁰ ; GO ⁵⁹ ; RJ ⁵⁹	–
<i>E. aerogenes</i>	CE ⁵⁹ ; DF ⁵⁹ ; PE ⁵⁹	–
<i>E. cloacae</i>	CE ⁵⁹ ; DF ⁵⁹ ; GO ⁵⁹ ; MG ⁵⁹ ; Porto Alegre, RS ^{60,61} ; Rio de Janeiro ^{59,62}	–
<i>E. gergoviae</i>	Recife, PE ⁶³	–
<i>E. hormaechei</i>	Rio de Janeiro ⁶⁴	–
<i>E. coli</i>	BA ⁵⁹ ; DF ⁵⁹ ; MG ⁵⁹ ; Recife, PE ^{59,65} ; Rio de Janeiro, RJ ^{59,66}	ST2 ⁵⁹ ; ST39 ⁵⁹ ; ST43 ⁵⁹ ; ST305 ⁵⁹ ; ST479 ⁵⁹ ; ST502 ⁶⁵ ; ST629 ⁵⁹ ; ST630 ⁵⁹ ; ST631 ⁵⁹ ; ST632 ⁵⁹
<i>K. pneumoniae</i>	AL ⁶⁷ ; AM ⁶⁷ ; Brasília, DF ⁶⁷ ; Campo Grande, MS ^{68,69} ; CE ⁶⁷ ; ES ^{67,70} ; Florianópolis, SC ^{67,71} ; Franca, SP ⁶⁰ ; GO ^{67,70} ; João Pessoa, PB ⁷² ; Lageado, RS ⁷³ ; MA ⁶⁷ ; MG ^{67,70} ; PE ^{67,70} ; PI ⁶⁷ ; Porto Alegre, RS ^{61,73,74} ; Recife, PE ^{28,56,65,67,75} ; Ribeirão Preto, SP ^{26,60} ; Rio de Janeiro, RJ ^{14,60,67,76} ; São Paulo, SP ^{27,77–80}	ST11 ^{26,60,67,70,80} ; ST13 ⁶⁷ ; ST16 ^{67,70} ; ST17 ⁶⁷ ; ST19 ⁶⁷ ; ST25 ^{67,70} ; ST55 ⁶⁷ ; ST70 ⁷⁰ ; ST101 ⁷⁰ ; ST138 ⁶⁷ ; ST258 ⁶⁰ ; ST323 ⁶⁷ ; ST340 ^{67,75} ; ST423 ⁷⁰ ; ST437 ^{60,67,72,80} ; ST442 ⁷⁰ ; ST443 ⁷⁰ ; ST756 ⁶⁷ ; ST757 ⁶⁷ ; ST758 ⁶⁷ ; ST759 ⁶⁷ ; ST760 ⁶⁷ ; ST837 ⁶⁷ ; ST838 ⁶⁷ ; ST839 ⁶⁷ ; ST840 ⁶⁷ ; ST841 ⁶⁷ ; ST842 ⁶⁷ ; ST855 ⁶⁷
<i>K. oxytoca</i>	Recife, PE ⁸¹ ; RJ ⁵⁹ ; MG ⁵⁹	–
<i>K. georgiana</i>	Porto Alegre, PA ⁸²	–
<i>M. morgani</i>	MG ⁵⁹	–
<i>P. agglomerans</i>	RJ ⁵⁹	–
<i>P. mirabilis</i>	Recife, PE ⁸³	–
<i>P. stuartii</i>	Recife, PE ⁸⁴ ; MG ⁵⁹	–
<i>S. marcescens</i>	Duque de Caxias, RJ ⁶⁰ ; Porto Alegre, RS ⁶¹ ; Recife, PE ^{59,85} ; Dourados, MS ⁵²	–

The following abbreviations correspond to Brazilian States: AL, Alagoas; AM, Amazonas; BA, Bahia; DF, Distrito Federal; ES, Espírito Santo; GO, Goiás; MA, Maranhão; MG, Minas Gerais; MS, Mato Grosso do Sul; PB, Paraíba; PE, Pernambuco; RJ, Rio de Janeiro; RS, Rio Grande do Sul; SC, Santa Catarina; SP, São Paulo.

of plasmid-mediated AmpC was 0.46% in outpatients and 1.8% in inpatients. The full nucleotide sequences were determined and *bla*_{CMY-2} was the most frequently detected gene, but *bla*_{CMY-4} was also detected.⁴⁶

The rise of carbapenemases in Brazil

Imipenem has been available for clinical use in Brazil since the end of the 80s. In 1989 a surveillance study, carried out with 1231 isolates, mainly from inpatients from five different medical centers from São Paulo, Rio de Janeiro and Salvador, reported a 1% imipenem resistance rate for *E. coli*, while this rate was 6% for *Enterobacter* sp. but resistant isolates were also found among *K. pneumoniae*.⁴⁷ In 1998, a ceftiprome susceptibility study also reported imipenem resistance in *Enterobacteriaceae*. Using commercial microdilution plates, 349 *Enterobacteriaceae* from tertiary hospitals from four different states were evaluated.⁴⁸ Imipenem resistance rate among *Enterobacter* species varied from 2 to 8%, while this rate among *K. pneumoniae* was 7%, but unfortunately, no further studies were published on those strains. In 2005, almost 20 years after the introduction of carbapenems in clinical use in Brazil, the first report of an *Enterobacteriaceae* producing a carbapenemase came out. The work of Lincopan et al. described the presence of IMP-1 in a *K. pneumoniae* strain detected in a patient from a university hospital from São Paulo, located at the Southeast of Brazil.⁴⁹ The same IMP-1-producing *K. pneumoniae* strain was detected in six distinct hospitals of the city of São Paulo between the years 2003 and 2005.⁵⁰ In one of these hospitals, it was responsible for causing an outbreak in an intensive care unit.⁵¹ IMP-1 was also detected in a *P. rettgeri* isolate that was co-producer of CTX-M-like, and SHV-like.⁵⁰

The co-production of IMP-10 and KPC-2 was detected in *S. marcescens* causing an outbreak in a tertiary, teaching hospital in Dourados, MS.⁵²

GES-5, an enzyme of the GES family with spectrum toward carbapenems, was initially detected in Brazil in a *K. pneumoniae* isolated from a rectal surveillance swab of an elderly patient admitted to a private hospital in São Paulo, in 2008. This isolate also showed deletions on *ompK35* and *ompK36* genes.⁵³ GES-5 was also detected in three genetically related *Kluyvera intermedia* that were isolated from one sink and two distinct taps of an intensive care unit of a tertiary-care hospital in Porto Alegre, in May 2013, during an environmental surveillance for NDM-1-producing isolates.⁵⁴ Although only reported in 2014, GES-5 was also recovered from the blood of an adult patient admitted to a university hospital in Porto Alegre, in 2011. The patient had acute myeloid leukemia and had recent exposure to multiple antibiotics.⁵⁵

The first report on the detection of *Klebsiella pneumoniae* carbapenemase (KPC) in Brazil was published in 2009,⁵⁶ and described the detection of KPC-2 in 2006, ten years after the first detection of KPC-2 in world, in 1996, in North Carolina, in the United States of America.^{57,58} The work described the detection of KPC-2 in *K. pneumoniae* in four patients from the city of Recife, located at the Northeast of Brazil. Earlier dissemination of KPC-2 production was later reported in São Paulo. Subsequently, KPC-2 was described in many *Enterobacteriaceae* species and locations all over Brazil (Table 2). To date this is the only variant reported from Brazil, although 23 variants (<http://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-data-resources/>) have been described worldwide.

KPC-2-producing *Enterobacteriaceae* are now disseminated all over Brazil but *K. pneumoniae* is the most frequent species. Among this species, ST11 and ST437, which belong to the

clonal complex 258, are the most frequently detected clonal groups (Table 2). A recent publication analyzed 3085 *K. pneumoniae* isolates cultivated from patients from 10 private hospitals from the great São Paulo urban area, during the period from January 2011 to December 2015. Most of the isolates were recovered from blood cultures. The work showed an amazing increase in the carbapenem resistance rate, from 6.8% in 2011 to 35.5% in 2015; of note, KPC-2 was detected in 96.2% of the carbapenem-resistant isolates, and there were both interhospital and intrahospital clonal dissemination.⁸⁰

New Delhi metallo- β -lactamase (NDM) was firstly detected in Brazil in 2013, in *Providencia rettgeri*, from a patient from Porto Alegre, a city located at the South of Brazil.⁸⁶ This detection occurred four years after the initial detection in a ST14 *K. pneumoniae* strain causing urinary tract infection and in an *E. coli* strain from feces from a Swedish patient of Indian origin.⁸⁷ Compared to what happened with KPC, which was detected in Brazil 10 years after the initial description, NDM-1-producing strains were detected much earlier, which indicates a great potential for more efficient dissemination in Brazil. This *P. rettgeri* strain was later shown to have heterogeneous carbapenem resistance, which could make its detection a challenging task.⁸⁸ Subsequently, expression of NDM-1 was reported in *E. hormaechei* from the same city where the first case had been detected.⁸⁹ *E. cloacae* complex strains and *Morganella morganii* expressing NDM-1 were also reported by other research group from Porto Alegre.⁹⁰ In the same year of 2013, the first complete nucleotide sequences of *bla*_{NDM-1}-bearing plasmids from Brazil were described, in *E. coli* and *E. hormaechei* cultured from the same rectal swab from a patient from Rio de Janeiro who had never been exposed to carbapenems. The *bla*_{NDM-1} gene was found to be located on a IncFIIk in *E. hormaechei* and on a IncX3 plasmid in a ST2 *E. coli*, but both plasmids contained a new structure designated Tn3000, that could possibly mediate the transposition of the *bla*_{NDM-1} gene.⁹¹ Subsequently, coproduction of NDM-1 and KPC-2 was described in *P. rettgeri* and *E. cloacae* from Rio de Janeiro.^{62,64}

More recently, a new class A carbapenemase, designated Brazilian *Klebsiella* carbapenemase (BKC-1) was described in Brazil.⁹² To date it has only been found in *K. pneumoniae* in a low frequency, possible due to the fact that the *bla*_{BKC-1} gene is located in a small transferable, non-conjugative plasmid.^{92,93}

Polymyxin resistance in carbapenem-resistant *K. pneumoniae*: a nightmare

The first report on polymyxin-resistance in Brazilian *Enterobacteriaceae* came out in 2006.⁹⁴ At that time, with a low colistin and polymyxin B clinical use, the polymyxin B resistance rate was 0.5% in *E. coli*, 1.8% in *K. pneumoniae* and 16.7% in *Enterobacter* spp. In a subsequent publication the same group evidenced a 3.0% resistance rate among *K. pneumoniae* in Latin America.⁹⁵ In 2013, Pereira et al. reported a 15% polymyxin resistance rate among KPC-producing *K. pneumoniae* from diverse Brazilian states.⁶⁷ Polymyxin resistance in *E. cloacae* and *K. pneumoniae* strains was also reported from Porto Alegre, south of Brazil.^{61,96} To date, interruption of *mgrB* gene by insertion sequences or missense mutations is the most frequent mechanism of polymyxin resistance in

K. pneumoniae in Brazil.^{93,97} The most recent evidence of the amazing polymyxin resistance problem in Brazil came from a report from São Paulo, the largest city in Latin America. The authors described a 35.5% carbapenem resistance rate due to KPC-2 production, among *K. pneumoniae* causing infections in 2015, and also found an increase in polymyxin B resistance among KPC-producing *K. pneumoniae*, from 0% in 2011 to 27.1% in 2015.⁸⁰ This increase coincided with the increased use of polymyxins as empiric therapy to treat severe infectious when Gram negatives are possible etiologic agents in intensive care units. More concerning was finding interhospital and intrahospital clonal dissemination and the fact that most isolates included in the study were detected from blood cultures. This is a therapeutic nightmare, since intravenous fosfomycin and ceftazidime-avibactam are still not available in Brazil.

Recently, the *mcr-1* (mobile colistin resistance) gene was detected in a clinical strain of *E. coli* ST101 from the Northeast of Brazil.⁹⁸ The authors found the gene located on a IncX4 plasmid, and consequently the selective pressure represented by the overuse of polymyxins could have contributed to the dissemination of this resistance mechanism.

In summary, antimicrobial resistance in *Enterobacteriaceae* in Brazil is a very serious problem that needs urgent actions which includes more strict adherence to infection control measures, more judicious use of antimicrobials in human and animal husbandries and fast approval of old and new antimicrobials like fosfomycin and ceftazidime-avibactam for clinical use in Brazil, in order to decrease the polymyxin consume. If these measures are not applied together, the release of ceftazidime-avibactam will be a partial measure that will be probably followed by dissemination of NDM-1 producers in Brazil.

Conflicts of interest

The authors declare no conflicts of interest.

REFERENCES

1. Fernandes MR, Trabulsi LR. Infectious resistance in pathogenic enteric organisms isolated in Sao Paulo, Brasil (preliminary report). *Rev Inst Med Trop Sao Paulo*. 1968;10(1):52-53.
2. Zuliani ME, Trabulsi LR. In vitro sensitivity of 166 *Shigella* strains isolated in Sao Paulo, Brazil, to sulphadiazine and five antibiotics. *Rev Inst Med Trop Sao Paulo*. 1968;10(2):70-77.
3. Costa GA, Hofer E. Resistance to chloramphenicol of *Salmonella typhi* samples isolated in various states of Brazil. *Hospital (Rio J)*. 1971;79(2):229-242.
4. Palmeira ML, Batalha PP, Gomes VL. On the appearance of multiple resistance to antibiotics and chemotherapeutic agents of *Shigella* strains isolated in Rio de Janeiro. *Mem Inst Oswaldo Cruz*. 1971;69(1):145-152.
5. Jones RN, Marshall SA. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study. *Diagn Microbiol Infect Dis*. 1994;19(1):33-38.
6. Gales AC, Bolmstrom A, Sampaio J, et al. Antimicrobial susceptibility of *Klebsiella pneumoniae* producing

- extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. *Braz J Infect Dis*. 1997;1(4):196–203.
7. Sader HS, Mimica I, Rossi F, et al. Evaluation of the in vitro activity of cefepime compared to other broad-spectrum cephalosporins against clinical isolates from eighteen Brazilian hospitals by using the Etest. *Diagn Microbiol Infect Dis*. 1997;28(2):87–92.
 8. Bonnet R, Sampaio JL, Labia R, et al. A novel CTX-M beta-lactamase (CTX-M-8) in cefotaxime-resistant Enterobacteriaceae isolated in Brazil. *Antimicrob Agents Chemother*. 2000;44(7):1936–1942.
 9. Bonnet R, Sampaio JL, Chanal C, et al. A novel class A extended-spectrum beta-lactamase (BES-1) in *Serratia marcescens* isolated in Brazil. *Antimicrob Agents Chemother*. 2000;44(11):3061–3068.
 10. Bonnet R, Dutour C, Sampaio JL, et al. Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly. *Antimicrob Agents Chemother*. 2001;45(8):2269–2275.
 11. Mendes C, Hsiung A, Kiffer C, et al. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in Brazil: MYSTIC Antimicrobial Surveillance Program. *Braz J Infect Dis*. 2000;4(5):236–244.
 12. Nogueira Kda S, Conte D, Maia FV, et al. Distribution of extended-spectrum beta-lactamase types in a Brazilian tertiary hospital. *Rev Soc Bras Med Trop*. 2015;48(2):162–169.
 13. Goncalves LF, de Oliveira Martins-Junior P, de Melo AB, et al. Multidrug resistance dissemination by extended-spectrum beta-lactamase-producing *Escherichia coli* causing community-acquired urinary tract infection in the Central-Western Region, Brazil. *J Glob Antimicrob Resist*. 2016;6:1–4.
 14. Peirano G, Seki LM, Val Passos VL, et al. Carbapenem-hydrolysing beta-lactamase KPC-2 in *Klebsiella pneumoniae* isolated in Rio de Janeiro, Brazil. *J Antimicrob Chemother*. 2009;63(2):265–268.
 15. Nogueira Kda S, Paganini MC, Conte A, et al. Emergence of extended-spectrum beta-lactamase producing *Enterobacter* spp. in patients with bacteremia in a tertiary hospital in southern Brazil. *Inferm Infec Microbiol Clin*. 2014;32(2):87–92.
 16. Minarini LA, Poirel L, Trevisani NA, et al. Predominance of CTX-M-type extended-spectrum beta-lactamase genes among enterobacterial isolates from outpatients in Brazil. *Diagn Microbiol Infect Dis*. 2009;65(2):202–206.
 17. Andrade LN, Minarini LA, Pitondo-Silva A, et al. Determinants of beta-lactam resistance in meningitis-causing Enterobacteriaceae in Brazil. *Can J Microbiol*. 2010;56(5):399–407.
 18. Berman H, Barberino MG, Moreira ED Jr, et al. Distribution of strain type and antimicrobial susceptibility of *Escherichia coli* isolates causing meningitis in a large urban setting in Brazil. *J Clin Microbiol*. 2014;52(5):1418–1422.
 19. Minarini LA, Camargo IL, Pitondo-Silva A, et al. Multilocus sequence typing of uropathogenic ESBL-producing *Escherichia coli* isolated in a Brazilian community. *Curr Microbiol*. 2007;55(6):524–529.
 20. Queiroz ML, Antunes P, Mourao J, et al. Characterization of extended-spectrum beta-lactamases, antimicrobial resistance genes, and plasmid content in *Escherichia coli* isolates from different sources in Rio de Janeiro, Brazil. *Diagn Microbiol Infect Dis*. 2012;74(1):91–94.
 21. Dropa M, Balsalobre LC, Lincopan N, et al. Complex class 1 integrons harboring CTX-M-2-encoding genes in clinical Enterobacteriaceae from a hospital in Brazil. *J Infect Dev Ctries*. 2015;9(8):890–897.
 22. Peirano G, Asensi MD, Pitondo-Silva A, et al. Molecular characteristics of extended-spectrum beta-lactamase-producing *Escherichia coli* from Rio de Janeiro, Brazil. *Clin Microbiol Infect*. 2011;17(7):1039–1043.
 23. de Oliveira Garcia D, Doi Y, Szabo D, et al. Multiclonal outbreak of *Klebsiella pneumoniae* producing extended-spectrum beta-lactamase CTX-M-2 and novel variant CTX-M-59 in a neonatal intensive care unit in Brazil. *Antimicrob Agents Chemother*. 2008;52(5):1790–1793.
 24. Lopes AC, Veras DL, Lima AM, et al. bla(CTX-M-2) and bla(CTX-M-28) extended-spectrum beta-lactamase genes and class 1 integrons in clinical isolates of *Klebsiella pneumoniae* from Brazil. *Mem Inst Oswaldo Cruz*. 2010;105(2):163–167.
 25. Ramos PI, Picao RC, Almeida LG, et al. Comparative analysis of the complete genome of KPC-2-producing *Klebsiella pneumoniae* Kp13 reveals remarkable genome plasticity and a wide repertoire of virulence and resistance mechanisms. *BMC Genomics*. 2014;15:54–69.
 26. Andrade LN, Vitali L, Gaspar GG, et al. Expansion and evolution of a virulent, extensively drug-resistant (polymyxin B-resistant), QnrS1-, CTX-M-2-, and KPC-2-producing *Klebsiella pneumoniae* ST11 international high-risk clone. *J Clin Microbiol*. 2014;52(7):2530–2535.
 27. Bueno MF, Francisco GR, O'Hara JA, et al. Coproduction of 16S rRNA methyltransferase RmtD or RmtG with KPC-2 and CTX-M group extended-spectrum beta-lactamases in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2013;57(5):2397–2400.
 28. Cabral AB, Melo Rde C, Maciel MA, et al. Multidrug resistance genes, including bla(KPC) and bla(CTX)-M-2, among *Klebsiella pneumoniae* isolated in Recife, Brazil. *Rev Soc Bras Med Trop*. 2012;45(5):572–578.
 29. Do Carmo Filho JR, Silva RM, Castanheira M, et al. Prevalence and genetic characterization of blaCTX-M among *Klebsiella pneumoniae* isolates collected in an intensive care unit in Brazil. *J Chemother*. 2008;20(5):600–603.
 30. Zavascki AP, Carvalhaes CG, da Silva GL, et al. Outbreak of carbapenem-resistant *Providencia stuartii* in an intensive care unit. *Infect Control Hosp Epidemiol*. 2012;33(6):627–630.
 31. Fernandes SA, Paterson DL, Ghilardi-Rodrigues AC, et al. CTX-M-2-producing *Salmonella typhimurium* isolated from pediatric patients and poultry in Brazil. *Microb Drug Resist*. 2009;15(4):317–321.
 32. Cergole-Novella MC, Guth BE, Castanheira M, et al. First description of bla(CTX-M-14)- and bla(CTX-M-15)-producing *Escherichia coli* isolates in Brazil. *Microb Drug Resist*. 2010;16(3):177–184.
 33. Seki LM, Pereira PS, de Souza Conceicao M, et al. Molecular epidemiology of CTX-M producing Enterobacteriaceae isolated from bloodstream infections in Rio de Janeiro, Brazil: emergence of CTX-M-15. *Braz J Infect Dis*. 2013;17(6):640–646.
 34. Peirano G, van der Bij AK, Freeman JL, et al. Characteristics of *Escherichia coli* sequence type 131 isolates that produce extended-spectrum beta-lactamases: global distribution of the H30-Rx sublineage. *Antimicrob Agents Chemother*. 2014;58(7):3762–3767.
 35. Tollentino FM, Polotto M, Nogueira ML, et al. High prevalence of bla(CTX-M) extended spectrum beta-lactamase genes in *Klebsiella pneumoniae* isolates from a tertiary care hospital: first report of bla(SHV-12), bla(SHV-31), bla(SHV-38), and bla(CTX-M-15) in Brazil. *Microb Drug Resist*. 2011;17(1):7–16.
 36. Dropa M, Ghiglione B, Matte MH, et al. Molecular and biochemical characterization of CTX-M-131, a natural Asp240Gly variant derived from CTX-M-2, produced by a *Providencia rettgeri* clinical strain in Sao Paulo, Brazil. *Antimicrob Agents Chemother*. 2015;59(3):1815–1817.
 37. Correa L, Martino MD, Siqueira I, et al. A hospital-based matched case-control study to identify clinical outcome and

- risk factors associated with carbapenem-resistant *Klebsiella pneumoniae* infection. *BMC Infect Dis*. 2013;13:80–87.
38. Dropa M, Balsalobre LC, Lincopan N, et al. Emergence of *Klebsiella pneumoniae* carrying the novel extended-spectrum beta-lactamase gene variants bla(SHV-40), bla(TEM-116) and the class 1 integron-associated bla(GES-7) in Brazil. *Clin Microbiol Infect*. 2010;16(6):630–632.
 39. Mendes C, Kiffer C, Segura A, et al. *Klebsiella pneumoniae* with multiple antimicrobial resistance. *Braz J Infect Dis*. 2004;8(1):109–111.
 40. Corkill JE, Cuevas LE, Gurgel RQ, et al. SHV-27, a novel cefotaxime-hydrolyzing beta-lactamase, identified in *Klebsiella pneumoniae* isolates from a Brazilian hospital. *J Antimicrob Chemother*. 2001;47(4):463–465.
 41. Veras DL, Alves LC, Brayner FA, et al. Prevalence of the bla(SHV) gene in *Klebsiella pneumoniae* isolates obtained from hospital and community infections and from the microbiota of healthy individuals in Recife, Brazil. *Curr Microbiol*. 2011;62(5):1610–1616.
 42. Pavez M, Neves P, Dropa M, et al. Emergence of carbapenem-resistant *Escherichia coli* producing CMY-2-type AmpC beta-lactamase in Brazil. *J Med Microbiol*. 2008;57(Pt 12):1590–1592.
 43. Castanheira M, Pereira AS, Nicoletti AG, et al. First report of plasmid-mediated qnrA1 in a ciprofloxacin-resistant *Escherichia coli* strain in Latin America. *Antimicrob Agents Chemother*. 2007;51(4):1527–1529.
 44. da Silva Dias RC, Borges-Neto AA, D'Almeida Ferraiuoli GI, et al. Prevalence of AmpC and other beta-lactamases in enterobacteria at a large urban university hospital in Brazil. *Diagn Microbiol Infect Dis*. 2008;60(1):79–87.
 45. Campana EH, Barbosa PP, Fehlberg LC, et al. Frequency of plasmid-mediated AmpC in Enterobacteriaceae isolated in a Brazilian Teaching Hospital. *Braz J Microbiol*. 2013;44(2):477–480.
 46. Rocha DA, Campos JC, Passadore LF, et al. Frequency of plasmid-mediated AmpC beta-lactamases in *Escherichia coli* isolates from urine samples in Sao Paulo, Brazil. *Microb Drug Resist*. 2016;22(4):321–327.
 47. de Godoy CV, Mendes CM, Mimica I, et al. In vitro susceptibility to a new antimicrobial agent (imipenem) of pathogens isolated from inpatients at various centers. *Rev Inst Med Trop Sao Paulo*. 1989;31(3):169–176.
 48. Sader HS, Mendes CM, Montelli A, et al. In vitro antimicrobial activity of ceftiprome compared to other broad-spectrum beta-lactam drugs against 804 clinical isolates from 9 Brazilian hospitals. *Rev Assoc Med Bras (1992)*. 1998;44(4):283–288.
 49. Lincopan N, McCulloch JA, Reinert C, et al. First isolation of metallo-beta-lactamase-producing multiresistant *Klebsiella pneumoniae* from a patient in Brazil. *J Clin Microbiol*. 2005;43(1):516–519.
 50. Lincopan N, Leis R, Vianello MA, et al. Enterobacteria producing extended-spectrum beta-lactamases and IMP-1 metallo-beta-lactamases isolated from Brazilian hospitals. *J Med Microbiol*. 2006;55(Pt 11):1611–1613.
 51. Penteado AP, Castanheira M, Pignatari AC, et al. Dissemination of bla(IMP-1)-carrying integron In86 among *Klebsiella pneumoniae* isolates harboring a new trimethoprim resistance gene dfr23. *Diagn Microbiol Infect Dis*. 2009;63(1):87–91.
 52. Silva KE, Cayo R, Carvalhaes CG, et al. Coproduction of KPC-2 and IMP-10 in carbapenem-resistant *Serratia marcescens* isolates from an outbreak in a Brazilian Teaching Hospital. *J Clin Microbiol*. 2015;53(7):2324–2328.
 53. Picao RC, Santos AF, Nicoletti AG, et al. Detection of GES-5-producing *Klebsiella pneumoniae* in Brazil. *J Antimicrob Chemother*. 2010;65(4):796–797.
 54. Ribeiro VB, Zavascki AP, Rozales FP, et al. Detection of bla(GES-5) in carbapenem-resistant *Klebsiella pneumoniae* isolates recovered from the hospital environment. *Antimicrob Agents Chemother*. 2014;58(1):622–623.
 55. Ribeiro VB, Falci DR, Rozales FP, et al. Carbapenem-resistant GES-5-producing *Klebsiella pneumoniae* in Southern Brazil. *Braz J Infect Dis*. 2014;18(2):231–232.
 56. Monteiro J, Santos AF, Asensi MD, et al. First report of KPC-2-producing *Klebsiella pneumoniae* strains in Brazil. *Antimicrob Agents Chemother*. 2009;53(1):333–334.
 57. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2001;45(4):1151–1161.
 58. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. *Clin Microbiol Rev*. 2007;20(3):440–458, table of contents.
 59. Tavares CP, Pereira PS, Marques Ede A, et al. Molecular epidemiology of KPC-2-producing Enterobacteriaceae (non-*Klebsiella pneumoniae*) isolated from Brazil. *Diagn Microbiol Infect Dis*. 2015;82(4):326–330.
 60. Andrade LN, Curiao T, Ferreira JC, et al. Dissemination of blaKPC-2 by the spread of *Klebsiella pneumoniae* clonal complex 258 clones (ST258, ST11, ST437) and plasmids (IncFII, IncN, IncL/M) among Enterobacteriaceae species in Brazil. *Antimicrob Agents Chemother*. 2011;55(7):3579–3583.
 61. Ribeiro VB, Andrade LN, Linhares AR, et al. Molecular characterization of *Klebsiella pneumoniae* carbapenemase-producing isolates in southern Brazil. *J Med Microbiol*. 2013;62(Pt 11):1721–1727.
 62. Quiles MG, Rocchetti TT, Fehlberg LC, et al. Unusual association of NDM-1 with KPC-2 and armA among Brazilian Enterobacteriaceae isolates. *Braz J Med Biol Res*. 2015;48(2):174–177.
 63. Almeida AC, de Castro KK, Fehlberg LC, et al. Carbapenem-resistant Enterobacter gergoviae harbouring blaKPC-2 in Brazil. *Int J Antimicrob Agents*. 2014;44(4):369–370.
 64. Pereira PS, Borghi M, Albano RM, et al. Coproduction of NDM-1 and KPC-2 in *Enterobacter hormaechei* from Brazil. *Microb Drug Resist*. 2015;21(2):234–236.
 65. Almeida AC, de Sa Cavalcanti FL, Vilela MA, et al. *Escherichia coli* ST502 and *Klebsiella pneumoniae* ST11 sharing an IncW plasmid harbouring the bla(KPC-2) gene in an Intensive Care Unit patient. *Int J Antimicrob Agents*. 2012;40(4):374–376.
 66. D'Alincourt Carvalho-Assef AP, Leao RS, da Silva RV, et al. *Escherichia coli* producing KPC-2 carbapenemase: first report in Brazil. *Diagn Microbiol Infect Dis*. 2010;68(3):337–338.
 67. Pereira PS, de Araujo CF, Seki LM, et al. Update of the molecular epidemiology of KPC-2-producing *Klebsiella pneumoniae* in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). *J Antimicrob Chemother*. 2013;68(2):312–316.
 68. Chang MR, Biberg CA, Lopes FA, et al. The first report of infection with *Klebsiella pneumoniae* carrying the bla(kpc) gene in State of Mato Grosso do Sul, Brazil. *Rev Soc Bras Med Trop*. 2013;46(1):114–115.
 69. Biberg CA, Rodrigues AC, do Carmo SF, et al. KPC-2-producing *Klebsiella pneumoniae* in a hospital in the Midwest region of Brazil. *Braz J Microbiol*. 2015;46(2):501–504.
 70. Seki LM, Pereira PS, de Souza Mda P, et al. Molecular epidemiology of KPC-2-producing *Klebsiella pneumoniae* isolates in Brazil: the predominance of sequence type 437. *Diagn Microbiol Infect Dis*. 2011;70(2):274–277.
 71. Zavascki AP, Zoccoli CM, Machado AB, et al. KPC-2-producing *Klebsiella pneumoniae* in Brazil: a widespread threat in waiting? *Int J Infect Dis*. 2010;14(6):pe539–pe540.
 72. Fehlberg LC, Carvalho AM, Campana EH, et al. Emergence of *Klebsiella pneumoniae*-producing KPC-2 carbapenemase in

- Paraíba, Northeastern Brazil. *Braz J Infect Dis*. 2012;16(6):577-580.
73. Zavascki AP, Machado AB, de Oliveira KR, et al. KPC-2-producing *Enterobacter cloacae* in two cities from Southern Brazil. *Int J Antimicrob Agents*. 2009;34(3):286-288.
74. Rodrigues Perez LR, Dias CG. Emergence of infections due to a polymyxin B-resistant KPC-2-producing *Klebsiella pneumoniae* in critically ill patients: what is the role of a previous colonization? *Infect Control Hosp Epidemiol*. 2016;37(2):240-241.
75. Martins WM, Almeida AC, Nicoletti AG, et al. Coproduction of KPC-2 and QnrB19 in *Klebsiella pneumoniae* ST340 isolate in Brazil. *Diagn Microbiol Infect Dis*. 2015;83(4):375-376.
76. Leao RS, Pereira RH, Folescu TW, et al. KPC-2 carbapenemase-producing *Klebsiella pneumoniae* isolates from patients with cystic fibrosis. *J Cyst Fibros*. 2011;10(2):140-142.
77. Pavez M, Mamizuka EM, Lincopan N. Early dissemination of KPC-2-producing *Klebsiella pneumoniae* strains in Brazil. *Antimicrob Agents Chemother*. 2009;53(6):2702.
78. Beirao EM, Furtado JJ, Girardello R, et al. Clinical and microbiological characterization of KPC-producing *Klebsiella pneumoniae* infections in Brazil. *Braz J Infect Dis*. 2011;15(1):69-73.
79. Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with *Klebsiella pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae* in solid organ transplantation. *Transpl Infect Dis*. 2012;14(2):198-205.
80. Bartolleti F, Seco BM, Capuzzo Dos Santos C, et al. Polymyxin B resistance in carbapenem-resistant *Klebsiella pneumoniae*, São Paulo, Brazil. *Emerg Infect Dis*. 2016;22(10):1849-1851.
81. Almeida AC, Cavalcanti FL, Martins WM, et al. First description of KPC-2-producing *Klebsiella oxytoca* in Brazil. *Antimicrob Agents Chemother*. 2013;57(8):4077-4078.
82. Ribeiro VB, Zavascki AP, Nodari CS, et al. Detection of blaKPC-2 in a carbapenem-resistant *Kluyvera georgiana*. *J Antimicrob Chemother*. 2012;67(11):2776-2777.
83. Cabral AB, Maciel MA, Barros JF, et al. Detection of bla KPC-2 in *Proteus mirabilis* in Brazil. *Rev Soc Bras Med Trop*. 2015;48(1):94-95.
84. Aires CA, Almeida AC, Vilela MA, et al. Selection of KPC-2-producing *Providencia stuartii* during treatment for septicemia. *Diagn Microbiol Infect Dis*. 2016;84(1):95-96.
85. Margate E, Magalhaes V, Fehlberg LC, et al. KPC-producing *Serratia marcescens* in a home-care patient from Recife, Brazil. *Rev Inst Med Trop Sao Paulo*. 2015;57(4):359-360.
86. Carvalho-Assef AP, Pereira PS, Albano RM, et al. Isolation of NDM-producing *Providencia rettgeri* in Brazil. *J Antimicrob Chemother*. 2013;68(12):2956-2957.
87. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in *Klebsiella pneumoniae* sequence type 14 from India. *Antimicrob Agents Chemother*. 2009;53(12):5046-5054.
88. Zavascki AP, Falci DR, da Silva RC, et al. Heteroresistance to carbapenems in New Delhi metallo-beta-lactamase-1-producing isolates: a challenge for detection? *Infect Control Hosp Epidemiol*. 2014;35(6):751-752.
89. Carvalho-Assef AP, Pereira PS, Albano RM, et al. Detection of NDM-1-CTX-M-15-, and qnrB4-producing *Enterobacter hormaechei* isolates in Brazil. *Antimicrob Agents Chemother*. 2014;58(4):2475-2476.
90. Rozales FP, Ribeiro VB, Magagnin CM, et al. Emergence of NDM-1-producing Enterobacteriaceae in Porto Alegre, Brazil. *Int J Infect Dis*. 2014;25:79-81.
91. Campos JC, da Silva MJ, dos Santos PR, et al. Characterization of Tn3000, a transposon responsible for blaNDM-1 dissemination among Enterobacteriaceae in Brazil, Nepal, Morocco, and India. *Antimicrob Agents Chemother*. 2015;59(12):7387-7395.
92. Nicoletti AG, Marcondes MF, Martins WM, et al. Characterization of BKC-1 class A carbapenemase from *Klebsiella pneumoniae* clinical isolates in Brazil. *Antimicrob Agents Chemother*. 2015;59(9):5159-5164.
93. Martins WM, Cordeiro-Moura JR, Ramos AC, et al. Comparison of phenotypic tests for detecting BKC-1-producing Enterobacteriaceae isolates. *Diagn Microbiol Infect Dis*. 2016;84(3):246-248.
94. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). *Clin Microbiol Infect*. 2006;12(4):315-321.
95. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). *J Antimicrob Chemother*. 2011;66(9):2070-2074.
96. Perez LR. Evaluation of polymyxin susceptibility profile among KPC-producing *Klebsiella pneumoniae* using Etest and MicroScan WalkAway automated system. *APMIS*. 2015;123(11):951-954.
97. Aires CA, Pereira PS, Asensi MD, et al. MgrB mutations mediating polymyxin B resistance in *Klebsiella pneumoniae* isolates from rectal surveillance swabs in Brazil. *Antimicrob Agents Chemother*. 2016;60(11):6969-6972.
98. Fernandes MR, McCulloch JA, Vianello MA, et al. First report of the globally disseminated IncX4 plasmid carrying the mcr-1 gene in a colistin-resistant *Escherichia coli* sequence Type 101 isolate from a human infection in Brazil. *Antimicrob Agents Chemother*. 2016;60(10):6415-6417.